NEW YORK, NY / ACCESSWIRE / June 13, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
PureCycle Technologies, Inc. (NASDAQ:PCT)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/purecycle-technologies-inc-loss-submission-form?prid=16827&wire=1
Lead Plaintiff Deadline: July 12, 2021
Class Period: November 16, 2020 - May 5, 2021
Allegations against PCT include that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle's financial projections are baseless; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Provention Bio, Inc. (NASDAQ:PRVB)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/provention-bio-inc-loss-submission-form?prid=16827&wire=1
Lead Plaintiff Deadline: July 20, 2021
Class Period: November 2, 2020 - April 8, 2021
Allegations against PRVB include that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16827&wire=1
Lead Plaintiff Deadline: August 2, 2021
Class Period: November 16, 2020 - March 22, 2021
Allegations against FREQ include that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: